Navigation Links
Cleveland researchers collaborate to launch Phase 1 clinical trial for new MS treatment
Date:8/23/2011

A team of researchers at three landmark Cleveland institutions have come together to launch a new clinical trial of an experimental treatment for multiple sclerosis (MS). Researchers at the Cleveland Clinic, University Hospitals Seidman Cancer Center, and Case Western Reserve University are collaborating on a ground-breaking study that will test the feasibility and safety of using the body's own stem cells to treat MS.

In patients with MS, the immune system abnormally attacks the central nervous system, causing damage to the nerve cells and their protective myelin sheath. The body has mechanisms that attempt to repair this damage; however, in MS, the repair cannot keep pace with the ongoing damage.

The Phase 1 trial involves harvesting a patient's mesenchymal stem cells (MSCs), which are primitive cells in the bone marrow, culturing them in a laboratory, and then injecting the MSCs intravenously back into the patient to see if the procedure is safe, decreases disease activity, and leads to improved repair.

The research team is headed up by Jeffrey Cohen, MD, of the Cleveland Clinic's Mellen Center for Multiple Sclerosis Treatment and Research, and is funded by a $2.75 million, four-year grant from the United States Department of Defense and a $1 million grant from the National Institutes of Health. Dr. Cohen is Director of the Mellen Center's Experimental Therapeutics Program and Professor of Medicine (Neurology) in the Cleveland Clinic Lerner College of Medicine of the Case Western Reserve University School of Medicine. He has taken a lead role in a large number of MS clinical trials, including a Phase 3 trial that led to the recent approval of the first oral therapy for MS.

"Currently, there are eight medications approved to treat MS. They slow the disease but none of them reverses it. The hope is that mesenchymal stem cells will lessen ongoing damage caused by MS and promote repair," said Dr. Cohen. "We're taking a ca
'/>"/>

Contact: George Stamatis
george.stamatis@uhhospitals.org
216-844-3667
University Hospitals Case Medical Center
Source:Eurekalert

Page: 1 2 3 4 5

Related biology news :

1. Radiation from Japan detected in Cleveland
2. Cleveland Clinic researchers honored for contributions to science and technology
3. Draft sequence of Neandertal genome wins the 2010 AAAS Newcomb Cleveland Prize, supported by Affymetrix
4. Cleveland Museum of Natural History scientist announces new horned dinosaur
5. Cleveland Clinic, CWRU dental researcher finds switch that turns on the spread of cancer
6. UT researchers develop algorithm to improve remote electrocardiography
7. TGen and DTU researchers track source of Haitian cholera outbreak
8. UH researchers explore treatments for breast and colon cancers
9. Not so fast -- researchers find that lasting evolutionary change takes about 1 million years
10. Joslin researchers identify new target for treatment of type 2 diabetes and prediabetes
11. Southampton researchers awarded $28 million to progress pioneering nutrition and respiratory research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... understand how the repeated climatic shifts over the ... of genetic diversity, a team of researchers led ... Ana Carnaval developed a new biodiversity metric called ... which the genetic variation within species is restricted ... professor of biology, and 14 other researchers from ...
(Date:8/29/2014)... news release is available in German . ... key players in the natural nitrogen cycle on Earth ... specialist bacteria were thought to depend on nitrite as ... led by Holger Daims, a microbiologist at the University ... use hydrogen as an alternative source of energy. The ...
(Date:8/29/2014)... such as the prolific bloomer Emiliania huxleyi , ... discovered. The finding contradicts the common view that ... on scarce supplies of thiamine in the ocean to ... about the ocean," says CIFAR Senior Fellow Alexandra ... paper with CIFAR fellows John Archibald (Dalhousie ...
Breaking Biology News(10 mins):CCNY team defines new biodiversity metric 2Hydrogen powers important nitrogen-transforming bacteria 2Hydrogen powers important nitrogen-transforming bacteria 3Not all phytoplankton in the ocean need to take their vitamins 2Not all phytoplankton in the ocean need to take their vitamins 3
... fittest survive has been called into question by new research ... A collaboration between the Universities of Exeter and Bath in ... in the US, challenges our current understanding of evolution by ... The work represents a new approach to studying evolution that ...
... done by Mark Lusk and colleagues at the Colorado ... solar cells. Their latest work describes how the size ... energy to electrons to generate electricity. The results ... ACS Nano . The advance provides evidence ...
... NeoProteomics Inc., a biomarker development and software ... Case Western Reserve University. The deal has potential ... diabetes, and inflammatory diseases. Proteomics is the ... structures of biological systems. NeoProteomics, founded in 2006 ...
Cached Biology News:Research shows not only the fittest survive 2Size matters: Smaller particles could make solar panels more efficient 2Case Western Reserve and NeoProteomics announce exclusive option 2
(Date:9/2/2014)... Opertech Bio, Inc., a company that ... approach to sensory evaluation, today announced the issuance ... Patent and Trademark Office, encompassing high-throughput sensory discrimination ... taste evaluation technology called Microtiter Operant Gustometer or ... for rapid characterization of taste sensory properties,” said ...
(Date:9/2/2014)... - Oncothyreon Inc. (Nasdaq: ONTY ) announced today that ... will present at the Rodman & Renshaw 16 th ... on Tuesday, Sept. 9, 2014 at 2:05 p.m. Eastern. ... presentation will be accessible by visiting the Oncothyreon website ... About Oncothyreon Oncothyreon is a biotechnology ...
(Date:9/2/2014)... Mount, NC (PRWEB) September 02, 2014 ... establishment of its 11th clinical research site: PMG Research ... assumed ownership and operation of the clinical research department ... further expanding PMG’s presence in eastern North Carolina. This ... patients. For the patients in Rocky Mount and the ...
(Date:9/2/2014)... The inventors of tinAway, a novel ... are seeking support for development costs through a crowdfunding ... http://igg.me/at/tinaway ), was launched on September 1, 2014. , ... and is based on ten years of neuroscience ... and software engineers, Dr. Ian Dixon and Mr. Tony ...
Breaking Biology Technology:Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2PMG Research Announces the Formation of its Eleventh Site 2PMG Research Announces the Formation of its Eleventh Site 3tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 2tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 3tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 4tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 5
... QUEBEC CITY, Aug. 12 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: ... on,endocrinology and oncology, today reported financial and operating results,for the ... Highlights, - Advancement of cetrorelix Phase 3 program ... trial: patient enrollment completed; - ...
... ST. LOUIS, Aug. 12 At the Board ... quarterly cash dividend of,$.13 per share. The dividend ... record on September 2, 2008., About Sigma-Aldrich: ... company. Our biochemical and organic chemical products and ...
... LI-COR Biosciences continues to,expand its offering of ... new IRDye(R) 680 Donkey Anti-Chicken IgG, IRDye ... IgG, and IRDye 800CW Goat,Anti-Rat IgG antibodies ... detection for multiple applications including,quantitative Westerns, In-Cell ...
Cached Biology Technology:AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results 2AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results 3AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results 4AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results 5AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results 6AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results 7
...
For use with SSP products or any application requiring agarose gel separation • Multiple formats available to meet various throughput needs • Includes replacement parts for each un...
...
Request Info...
Biology Products: